earnings boost, page-13

Elle ... didn't really researched on patent expiration but what bioshares said

"Risks
The main risk for the company is that it will not achieve the necessary market penetration over the next three years. The core Quantiferon patent expires in 2012 and the company has patents,or rights to patents, over antigens that run out to 2017. There is a need to ensure the product is well engrained into the healthcare system well before the expiration of patents and competition from
generic tests."


Forrest ... Short term for me means about 3-4 years. I believe if they have money then management would rather spend on building the company which could be buying another company that compliment their business or even develop more products. It would be good if they give some dividends within 18 months. I am expecting strong sales in the next report based on the quarterly growth figures.